Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Status:
RECRUITING
Trial end date:
2031-08-01
Target enrollment:
Participant gender:
Summary
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.